证券日报网讯 1月13日，中赋科技在互动平台回答投资者提问时表示，公司会从提升上市公司持续盈利 能力、优化资产质量的长远目标出发，择机投资生物医药领域优质项目，培育新的利润增长点。具体业 务情况请以公司披露的定期报告及临时公告为准。 （文章来源：证券日报） ...

顺灏股份公告称，公司拟向参股子公司轨道辰光增资7498.04万元，增资完成后持股比例将从19.30%升 至28.68%，不会导致合并报表范围变动。轨道辰光董事长为公司董事张善从、法定代表人是公司联席 总裁张哲宇，本次增资构成关联交易。轨道辰光2025年1-9月营收1763.67万元、净利润-38.36万元。此 次增资利于完善公司投资布局，但轨道辰光业务受多因素影响，存在产业化、商业化落地周期长及不达 预期风险。 ...

Core Viewpoint - Hengtong Co., Ltd. (600226) is actively engaged in the research, production, and sales of its main business areas, which include electrolytic copper foil, veterinary pharmaceuticals, feed additives, and cogeneration [1] Business Overview - The company has made investments and strategic arrangements around its main business, indicating a proactive approach to growth and diversification [1] - Hengtong and its wholly-owned subsidiaries have invested in and hold stakes in several companies, including Qingdao Yibang Bioengineering Co., Ltd. (17.45% stake), Hebei Shengxue Dacheng Pharmaceutical Co., Ltd. (49% stake), and Zhejiang Ikobike Animal Health Products Co., Ltd. (49% stake) [1]